Jump Financial LLC Raises Position in 10x Genomics, Inc. (NASDAQ:TXG)

Jump Financial LLC grew its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 14.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,101 shares of the company’s stock after acquiring an additional 22,789 shares during the period. Jump Financial LLC’s holdings in 10x Genomics were worth $2,658,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Signaturefd LLC increased its stake in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after purchasing an additional 1,452 shares in the last quarter. Blue Trust Inc. raised its stake in 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares during the period. Sound Income Strategies LLC lifted its holdings in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in 10x Genomics in the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. grew its holdings in 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after buying an additional 4,324 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the stock in a transaction dated Friday, February 21st. The stock was purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the transaction, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company’s stock.

10x Genomics Trading Down 6.5 %

Shares of TXG opened at $7.51 on Friday. The firm has a fifty day moving average price of $9.96 and a 200-day moving average price of $13.61. The firm has a market capitalization of $918.49 million, a P/E ratio of -4.94 and a beta of 2.01. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $29.45.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on TXG shares. UBS Group lowered their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group cut their price objective on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Citigroup decreased their target price on 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, Leerink Partnrs cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus target price of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.